CoChat

Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes

Timmis, Adam D., Chaitman, Bernard R., Crager, Michael · 2006 · European Heart Journal

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Abstract

AIMS: The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabetic patients included in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial (JAMA 2004;291:309) were studied. Glycaemic control was also assessed in CARISA and its long-term open-label extension study. METHODS AND RESULTS: Patients with chronic angina enrolled in CARISA (189 with diabetes, 634 without diabetes) on background atenolol, diltiazem, or amlodipine therapy were randomized to placebo, ranolazine 750 or 1000 mg twice daily for 12 weeks, during which exercise tolerance, angina frequency, nitroglycerin usage, glucose, HbA(1c), and lipids were measured. Patients completing the randomized study could enroll in an ongoing open-label extension study and were evaluated every 3 months. Ranolazine produced similar improvements in exercise parameters, nitroglycerin use, and angina frequency in diabetic and non-diabetic patients. Adverse events were similar between groups. Fasting glucose and lipids remained unaltered in diabetic patients after 12 weeks of therapy. In a post hoc analysis, ranolazine 750 and 1000 mg reduced HbA(1c) vs. placebo by 0.48+/-0.18% (P=0.008) and 0.70+/-0.18% (P=0.0002), respectively; the HbA(1c) levels appeared to remain unchanged over time during long-term therapy. CONCLUSION: Anti-anginal efficacy and safety of ranolazine for angina were similar between diabetic and non-diabetic patients. Ranolazine significantly improved glycaemic control in diabetic patients.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehi495

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 1

  1. McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, Davis R, Field R, Frost G, Marshall S, Roddick J, Tesfaye S, Withers H, Suckling R, Smith S, Griffin S, Kaltenthaler E, Peters J, Feder G. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield: University of Sheffield; 2001.

Cited by

See all 193

Metadata

Authors
Timmis, A. D., Chaitman, B. R., & Crager, M.
Affiliations
London Chest Hospital (GB)
Corresponding author
Timmis, Adam D.
Venue
European Heart Journal
Published
2005-09-21
Volume
27
Issue
1
Pages
42-48
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2169525160
Cited by
193
References
26
Citations by year
2026: 5 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 7 · 2020: 9 · 2019: 10 · 2018: 8 · 2017: 10 · 2016: 14 · 2015: 10 · 2014: 15 · 2013: 19 · 2012: 12
FWCI
5.67
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
ranolazine, stable angina, diabetes mellitus, glycemic control, HbA1c, exercise tolerance, nitroglycerin use, angina frequency, adverse events
MeSH terms
Ranolazine, Acetanilides, Aged, Angina Pectoris, Chronic Disease, Diabetic Angiopathies, Double-Blind Method, Enzyme Inhibitors, Female, Nitroglycerin, Glycated Hemoglobin, Humans, Male, Piperazines, Vasodilator Agents, Treatment Outcome, Exercise Tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. https://app.cochat.ai/papers/10.1093/eurheartj/ehi495
The paper
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006). Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.